{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:19:07Z","timestamp":1784366347414,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.intimp.2022.108766","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:34:45Z","timestamp":1649291685000},"page":"108766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period"],"prefix":"10.1016","volume":"108","author":[{"given":"Manojit","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Ranjan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govindasamy","family":"Agoramoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjib","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.intimp.2022.108766_b0005","doi-asserted-by":"crossref","first-page":"R918","DOI":"10.1016\/j.cub.2021.06.049","article-title":"The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic","volume":"31","author":"Otto","year":"2021","journal-title":"Curr. Biol."},{"issue":"24","key":"10.1016\/j.intimp.2022.108766_b0010","doi-asserted-by":"crossref","first-page":"2100509","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509","article-title":"Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021","volume":"26","author":"Campbell","year":"2021","journal-title":"Eurosurveillance"},{"issue":"7858","key":"10.1016\/j.intimp.2022.108766_b0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2022.108766_b0020","doi-asserted-by":"crossref","first-page":"e01140","DOI":"10.1128\/mBio.01140-21","article-title":"Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Mbio"},{"key":"10.1016\/j.intimp.2022.108766_b0025","first-page":"e2270","article-title":"Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity","author":"Chakraborty","year":"2021","journal-title":"Rev. Med. Virol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108766_b0030","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108766_b0035","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2022.108766_b0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/CMR.00097-13","article-title":"CD4+ T Cells: guardians of the phagosome","volume":"27","author":"Tubo","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2022.108766_b0045","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T cell response to respiratory virus infections","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"issue":"7821","key":"10.1016\/j.intimp.2022.108766_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"issue":"6529","key":"10.1016\/j.intimp.2022.108766_b0055","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.intimp.2022.108766_b0060","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.intimp.2022.108766_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-021-03674-1","article-title":"Waning COVID super-immunity raises questions about Omicron","author":"Kozlov","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2022.108766_b0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4103\/ijmr.IJMR_2131_20","article-title":"First confirmed case of COVID-19 infection in India: A case report","volume":"151","author":"Andrews","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.intimp.2022.108766_b0075","article-title":"District level correlates of COVID-19 pandemic in India","author":"Tamrakar","year":"2020","journal-title":"PlosOne"},{"issue":"3","key":"10.1016\/j.intimp.2022.108766_b0080","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dsx.2021.05.009","article-title":"Differences between First wave and Second wave of COVID-19 in India","volume":"15","author":"Jain","year":"2021","journal-title":"Diab. Metabolic Syndrome"},{"key":"10.1016\/j.intimp.2022.108766_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2021.05.018","article-title":"The current second wave and COVID-19 vaccination status in India","volume":"96","author":"Chakraborty","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.intimp.2022.108766_b0090","doi-asserted-by":"crossref","first-page":"36:100915","DOI":"10.1016\/j.eclinm.2021.100915","article-title":"Second wave of COVID-19 pandemic in India: Barriers to effective governmental response","volume":"36","author":"Kar","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.intimp.2022.108766_b0095","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2213-2600(21)00312-X","article-title":"Implications of the second wave of COVID-19 in India","volume":"9","author":"Asrani","year":"2021","journal-title":"Lancet Respirat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.108766_b0100","doi-asserted-by":"crossref","first-page":"taab082","DOI":"10.1093\/jtm\/taab082","article-title":"Second wave of COVID-19: emergency situation in India","volume":"28","author":"Kumar","year":"2021","journal-title":"J. Travel Med."},{"issue":"6549","key":"10.1016\/j.intimp.2022.108766_b0105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Crotty","year":"2021","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.intimp.2022.108766_b0110","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.intimp.2022.108766_b0115","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.intimp.2022.108766_b0120","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2022.108766_b0125","doi-asserted-by":"crossref","first-page":"e149154","DOI":"10.1172\/JCI149154","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"6549","key":"10.1016\/j.intimp.2022.108766_b0130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"issue":"58","key":"10.1016\/j.intimp.2022.108766_b0135","doi-asserted-by":"crossref","first-page":"p.eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"issue":"7889","key":"10.1016\/j.intimp.2022.108766_b0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.108766_b0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/d41586-021-00728-2","article-title":"Five reasons why COVID herd immunity is probably impossible","author":"Aschwanden","year":"2021","journal-title":"Nature"},{"issue":"10263","key":"10.1016\/j.intimp.2022.108766_b0150","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson","year":"2020","journal-title":"The Lancet"},{"issue":"19","key":"10.1016\/j.intimp.2022.108766_b0155","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.2021.19623","article-title":"Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar","volume":"326","author":"Abu-Raddad","year":"2021","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.intimp.2022.108766_b0160","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm7032e1","article-title":"Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination\u2014Kentucky, May\u2013June 2021","volume":"70","author":"Cavanaugh","year":"2021","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.intimp.2022.108766_b0165","first-page":"ciab999","article-title":"Duration of SARS-CoV-2 natural immunity and protection against the Delta variant: a retrospective cohort study","author":"Kim","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2022.108766_b0170","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1002\/jmv.26982","article-title":"Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection","volume":"93","author":"Callegaro","year":"2021","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108766_b0175","doi-asserted-by":"crossref","first-page":"e149150","DOI":"10.1172\/JCI149150","article-title":"First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19","volume":"131","author":"Mazzoni","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"20","key":"10.1016\/j.intimp.2022.108766_b0180","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108766_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7889","key":"10.1016\/j.intimp.2022.108766_b0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2022.108766_b0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2022.108766_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-25479-6","article-title":"Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum","volume":"12","author":"Bates","year":"2021","journal-title":"Nat. Commun."},{"issue":"58","key":"10.1016\/j.intimp.2022.108766_b0205","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals after mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"issue":"6549","key":"10.1016\/j.intimp.2022.108766_b0210","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.intimp.2022.108766_b0215","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/vaccines9060600","article-title":"Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis","volume":"9","author":"Chakraborty","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.intimp.2022.108766_b0220","article-title":"Covid-19: The significance of India\u2019s emerging \u201chybrid immunity\u201d","volume":"375","author":"Thiagarajan","year":"2021","journal-title":"bmj"},{"issue":"2","key":"10.1016\/j.intimp.2022.108766_b0225","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2665-9913(21)00356-8","article-title":"Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases","volume":"4","author":"Shenoy","year":"2022","journal-title":"Lancet Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922002508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:52:11Z","timestamp":1761587531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922002508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"alternative-id":["S1567576922002508"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108766","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108766"}}